---
title: 'BRAF<sup>V600E</sup>-Mutant Metastatic Colorectal Cancer: Current Evidence,
  Future Directions, and Research Priorities'
date: '2024-05-30'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38816264/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240531182159&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: BRAF^(V600E)-mutant metastatic colorectal cancer represents a distinct
  molecular phenotype known for its aggressive biological behavior, resistance to
  standard therapies, and poor survival rates. Improved understanding of the biology
  of the BRAF oncogene has led to the development of targeted therapies that have
  paved the way for a paradigm shift in managing this disease. However, despite significant
  recent advancements, responses to targeted therapies are short-lived, and several
  ...
disable_comments: true
---
BRAF^(V600E)-mutant metastatic colorectal cancer represents a distinct molecular phenotype known for its aggressive biological behavior, resistance to standard therapies, and poor survival rates. Improved understanding of the biology of the BRAF oncogene has led to the development of targeted therapies that have paved the way for a paradigm shift in managing this disease. However, despite significant recent advancements, responses to targeted therapies are short-lived, and several ...